Mereo BioPharma (MREO) Amortization of Deferred Charges (2023 - 2026)

Mereo BioPharma (MREO) has reported Amortization of Deferred Charges for 4 consecutive years, with $134000.0 the latest figure, recorded in Q1 2026.

• Quarterly Amortization of Deferred Charges rose 6.35% year-over-year to $134000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $535000.0 (up 5.52% YoY) and the FY2025 annual result came in at $527000.0, up 3.94% from the prior year.
• Amortization of Deferred Charges grew to $134000.0 in Q1 2026 per MREO's latest filing, from $132000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for MREO reached as high as $136000.0 in Q2 2025 and fell as low as $121000.0 in Q1 2023.
• A 4-year average of $127923.1 and a median of $126000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
• The largest YoY upside for Amortization of Deferred Charges was 7.94% in 2025 against a maximum downside of 0.0% in 2025.
• Year by year, Amortization of Deferred Charges stood at $124000.0 in 2023, then climbed by 1.61% to $126000.0 in 2024, then climbed by 4.76% to $132000.0 in 2025, then grew by 1.52% to $134000.0 in 2026.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $134000.0, $132000.0, and $133000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.